Global guideline for type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 104, Issue 1, 2014, Pages 1-52

  Aschner, Pablo ^a   Beck Nielsen, Henning ^a   Bennett, Peter ^a   Boulton, Andrew ^a   Colagiuri, Ruth ^a   Colagiuri, Stephen ^a   McGill, Marg ^a   Sim, Kyra ^a   Franz, Marion ^a   Gadsby, Roger ^a   Gagliardino, Juan José ^a   Home, Philip ^a   Marshall, Sally ^a   Manley, Susan ^a   Mbanya, Jean Claude ^a   Neil, Andrew ^a   Ramachandran, Ambady ^a   Viswanathan, Vijay ^a   Ramaiya, Kaushik ^a   Roglic, Gojka ^a   Schaper, Nicolaas ^a   Siminerio, Linda ^a   Sinclair, Alan ^a   Snoek, Frank ^a   Van Crombrugge, Paul ^a   Vespasiani, Giacomo ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; COPING BEHAVIOR; DIABETES CONTROL; DIABETES EDUCATION; ELDERLY CARE; EYE EXAMINATION; FOOT CARE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH PROGRAM; HOSPITAL PATIENT; HUMAN; KIDNEY INJURY; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; NERVE INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SCREENING TEST; SELF MONITORING; BLOOD; CARDIOVASCULAR DISEASES; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HEALTH; INTERNATIONAL COOPERATION; METABOLISM;

GLYCOSYLATED HEMOGLOBIN;

CARDIOVASCULAR DISEASES; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLOBAL HEALTH; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERNATIONAL AGENCIES;

EID: 84898540957     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.10.001     Document Type: Article

References (324)

1. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. WHO/NMH/MNC/03.1 Geneva: WHO Department of Noncommunicable Disease Management; 2003. http://www.who.int.
2. Spijkerman AMW, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care 2003; 26: 2604-2608.
3. Spijkerman AMW, Henry RMA, Dekker JM, et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 2004; 256: 429-436.
4. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
5. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321
6. Lauritzen T, Griffin S, Borch-Johnsen K, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24: S6-S11.
7. Schellhase KG, Koepsell TD, Weiss NS, et al. Glucose screening and the risk of complications in type 2 diabetes mellitus. J Clin Epidemiol 2003; 56: 75-80.
8. Schneider H, Ehrlich M, Lischinski M, et al. Bewirkte das flächendeckende glukosurie-screening der 60er und 70er jahre im Osten Deutschlands tatsächlich den erhofften Prognosevorteil für die frühzeitig entdeckten Diabetiker? Diabetes Stoffwech 1996; 5: 33-38.
9. Colagiuri S, Cull CA, Holman RA. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UKPDS 61. Diabetes Care 2002; 25: 1410-1417.
10. Noble D, Mathur R, Dent T, et al. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011; 343: 7163.
11. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731.
12. Engelgau MM, Narayan KMV, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23: 1563-1580.
13. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006. http://www.who.int.
14. Report of a World Health Organization Consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011; 93: 299-309.
15. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
16. National Collaborating Centre for Women's and Children's Health and the National Collaborating Centre for Chronic Conditions. Diagnosis and management of type 1 diabetes in children young people and adults. London: National Institute for Clinical Excellence; 2004. http://www.nice.org.uk/ CG015NICEguideline.
17. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycaemic control. JAMA 2006; 296: 427-440.
18. Renders CM, Valk GD, Griffin SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001; 24: 821-833.
19. Griffin S, Kinmonth AL. Diabetes care: the effectiveness of systems for routine surveillance for people with diabetes. Cochrane DB Syst Rev 2000; 2: CD000541.
20. Klonoff DC. Diabetes and telemedicine. Is the technology sound, effective, cost-effective and practical? Diabetes Care 2003; 26: 1626-1628.
21. Janna M, Pare G. Home telemonitoring of patients with diabetes: a systematic assessment of observed effects. J Eval Clin Pract 2006; 13: 242-253.
22. Davidson MB. The effectiveness of nurse and pharmacist directed care in diabetes disease management: a narrative review. Curr Diab Rev 2007; 3: 280-287.
23. Department of Health. National service framework for diabetes: delivery strategy. London: Department of Health; 2002. http://www.doh.gov.uk/nsf/diabetes/research.
24. Griffiths C, Foster G, Ramsay J, et al. How effective are expert patient (lay led) education programmes for chronic disease. BMJ 2007; 334: 1254-1256.
25. Norris SL, Chowdhury FM, Van Let K, et al. Effectiveness of community health workers in the care of persons with diabetes. Diab Med 2006; 23: 544-556.
26. Campbell S, Reeves D, Kontopantelis E, et al. Quality of primary care in England with the introduction of pay for performance. N Eng J Med 2007; 357: 181-190.
27. Khunti K, Gadsby R, Millett C, et al. Quality of diabetes care in the UK: comparison of published quality of care reports with results from the quality and outcomes framework for diabetes. Diab Med 2007; 24: 1436-1441.
28. Alshamsan R, Millett C, Majeed A. Has pay for performance improved the management of diabetes in the United Kingdom? Prim Care Diabetes 2010; 4: 73-78.
29. Norris SL, Engelgau MM, Narayan KMV. Effectiveness of selfmanagement training in type 2 diabetes. A systematic review of randomized controlled trials. Diabetes Care 2001; 24: 561-587.
30. Colagiuri R, Girgis S, Eigenmann C, et al. National evidenced based guideline for patient education in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009.
31. Mulcahy K, Maryniuk M, Peeples M, et al. Diabetes self-management education core outcome measures. Diabetes Educator 2003; 29: 768-803.
32. Barlow JH, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns 2002; 48: 177-187.
33. Funnell, M, Brown T, Childs B, et al. National standards for diabetes self-management education. Diabetes Care 2007; 30: 1630-1637.
34. Funnell M, Tang TS, Anderson RM. From DSME to DSMS: developing empowerment based diabetes self-management support. Diabetes Spectrum 2007; 20: 221-216.
35. Mulcahy K, Maryniuk M, Peeples M, et al. Diabetes self-management education core outcome measures. Diabetes Educator 2003; 29: 768-803.
36. Brown SA. Meta-analysis of diabetes patient education research: variations in intervention effects across studies. Res Nurs Health 1992; 15: 409-419.
37. Glasgow RE, Osteen VL. Evaluating diabetes education. Are we measuring the most important outcomes? Diabetes Care 1992; 15: 1423-1432.
38. Lorig KR, Sobel DS, Stewart AL, et al. Evidence suggesting that a chronic disease self management program can improve health status while reducing hospitalization. Med Care 1999; 37: 5-14.
39. Duke SAS, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane DB Syst Rev 2009; 1: CD005268.
40. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff 2001; 20: 64-78.
41. Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes. Diabetes Care 2002; 25: 1159-1171.
42. Bodenheimer TS, Lorig K, Holman H, et al. Patient selfmanagement of chronic disease in primary care. JAMA 2002; 288: 2469-2475.
43. National Institute for Clinical Excellence. Technology Appraisal 60. Guidance on the use of patient-education models for diabetes. London: National Institute for Clinical Excellence; 2003. http://www.nice.org.uk.
44. Piette JD, Glasgow RE. Education and home glucose monitoring. In: Gerstein HC, Haynes RB (eds). Evidence based diabetes care. Hamilton, Ontario: BC Decker; 2001: 207-2051.
45. Gary TL, Genkinger JM, Gualler E, et al. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educator 2003; 29: 488-501.
46. Warsi A, Wang PS, LaValley MP, et al. Self-management education programs in chronic disease. A systematic review and methodological critique of the literature. Arch Intern Med 2004; 164: 1641-1649.
47. Fisher EB, Brownson CA, O'Toole ML, et al. Ecological approaches to self-management: the case of diabetes. Am J Public Health 2005; 95: 1523-1535.
48. Siminerio L, Piatt G, Emerson S, et al. Deploying the chronic care model to implement and sustain diabetes selfmanagement training programs. Diabetes Educator 2006; 32: 1-8.
49. Peyrot M, Rubin R, Funnell M, et al. Access to diabetes selfmanagement education: results of national surveys of patients, educators and physicians. Diabetes Educator 2009; 35: 246-263.
50. Osborn CY, Fisher JD. Diabetes education. Integrating theory, cultural considerations, and individually tailored content. Clin Diab 2008; 26: 148-150.
51. Skinner TS, Carey ME, Cradock S, et al, the DESMOND Collaborative. Educator talk and patient change: some insights from the DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) randomized controlled trial. Diab Med 2008; 25: 1117-1120.
52. Albano MG, Crozet C, d'Ivernois JF. Analysis of the 2004-2007 literature on therapeutic patient education in diabetes: results and trends. Acta Diabetol 2008; 45: 211-219.
53. Heisler M. Building peer support programs to manage chronic disease: seven models for success. Oakland, CA: California Health Care Foundation; 2006.
54. Lewin S, Dick J, Pond P, et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane DB Syst Rev 2005; 17: CD004015.
55. Rotheram-Borus MJ, Tomlinson M, Gwegwe M, et al. Diabetes buddies: peer support through a mobile phone buddy system. Diabetes Educator 2012; 38: 357-365.
56. Henkel V, Mergl R, Kohnen R, et al. Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ 2003; 326: 200-201. http://www. who-5.org.
57. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item shortform health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263. http://www.SF-36.org.
58. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. Diabetes Care 1995; 18: 754-760. http://www.proqolid.org.
59. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 3: 385-401.
60. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes. A metaanalysis. Diabetes Care 2001; 24: 1069-1078.
61. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001; 63: 619-630.
62. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004; 27: 2154-2160.
63. Egede LE, Zheng P, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25: 464-470.
64. Simon GE, Katon WS, Lin EH, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007; 64: 65-72.
65. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http://www.diabetes.ca.
66. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes: a national clinical guideline, 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
67. The National Collaborating Centre for Chronic Conditions. Type 1 diabetes in adults. National clinical guideline for diagnosis and management in primary and secondary care. http://www.rcplondon.ac.uk/pubs/books/DIA/index.asp.
68. Colagiuri R, Girgis S, Eigenmann C, et al. National evidenced based guideline for patient education in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009.
69. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
70. Petrak F, Herpertz S, Albus C, et al. Psychosocial factors and diabetes mellitus: evidence-based treatment guidelines. Curr Diabetes Rev 2005; 1: 255-270. http://www.diabetespsychologie. de/en/guidelines.htm.
71. Li C, Ford ES, Zhao G, et al. Prevalence and correlates of depression among U.S. adults with diabetes. The behavioral risk factor surveillance system 2006. Diab Res Clin Pract 2009; 83: 268-279.
72. van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 2010; 32: 380-395.
73. van Bastelaar KM, Pouwer F, Cuijpers P, et al. Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2011; 34: 320-325.
74. Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med 1998; 129: 613-621.
75. Snoek FJ, Skinner TC. Psychological counselling in problematic diabetes. Does it help? Diabet Med 2004; 19: 265-273.
76. Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363: 1589-1597.
77. Snoek F, Kersch NY, Eldrup E, et al. Monitoring of Individual Needs in Diabetes (MIND): baseline data from the crossnational Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. Diabetes Care 2011; 34: 601-603.
78. Pastors JG, Franz MJ. Effectiveness of medical nutrition therapy in diabetes. In: Franz MJ, Evert AB (eds). American Diabetes Association guide to nutrition therapy for diabetes. 2nd ed. Alexandria, VA: American Diabetes Association; 2012: 1-18.
79. Balducci S, Zanuso S, Cardell P, et al, the Italian Diabetes Exercise Study (IDES) Investigators. Changes in physical fitness predict improvements in modifiable cardiovascular risk factors independently of body weight loss in subjects with type 2 diabetes participating in the Italian Diabetes and Exercise Study (IDES). Diabetes Care 2012; 35: 1347-1354.
80. Herman WH, Hoerger TJ, Brandles M, et al, the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-332.
81. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005; 28: 888-894.
82. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http://www.diabetes.ca.
83. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
84. Colagiuri S, Dickinson S, Girgis S, et al. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009. http:// www.nhmrc.gov.au/guidelines/publications/di19.
85. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
86. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31: S61- S78. [Erratum in Diabetes Care 2010; 33: 1911].
87. The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes care 2007; 30: 1374-1383.
88. UK Prospective Diabetes Study Group. Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients (UKPDS 7). Metabolism 1990; 39: 905-912.
89. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
90. Goldhaber-Fiebert JD, Goldhaber-Fiebert SN, Tristan ML, et al. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetic patients in rural Costa Rica. Diabetes Care 2003; 26: 24-29.
91. Ziemer DC, Berkowitz KJ, Panayioto RM, et al. A simple meal plan emphasizing healthy food choices is as effective as an exchange-based meal plan for urban African Americans with type 2 diabetes. Diabetes Care 2003; 26: 1719-1724.
92. Lemon CC, Lacey K, Lohse B, et al. Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. J Am Diet Assoc 2004; 104: 1805- 1815.
93. Polonsky WH, Earles J, Smith S, et al. Integrating medical management with diabetes self-management training. A randomized control trial of the diabetes outpatient intensive treatment program. Diabetes Care 2003; 26: 3048-3053.
94. Banister NA, Jastrow ST, Hodges V, et al. Diabetes selfmanagement training program in a community clinic improves patient outcomes at modest cost. J Am Diet Assoc 2004; 104: 807-810.
95. Andrews RC, Cooper AR, Montgomery AA, et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the early ACTID randomized controlled trial. Lancet 2011; 378: 129-139.
96. Coppell KJ, Kataoka M, Williams SM, et al. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimized drug treatment: Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomized controlled trial. BMJ 2010; 341: c3337.
97. Academy of Nutrition and Dietetics. Disorders of lipid metabolism evidence-based nutrition practice guidelines, 2011. http://www.adaevidencelibrary.com/topic. cfm?cat=26519. Accessed: 26 June 2012.
98. Whitworth JA, Chalmers J. World Health Organization- International Society of Hypertension (WHO/ISH) hypertension guidelines. Clin Exp Hypertension 2004; 26: 747-752.
99. Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus. A meta-analysis of controlled clinical trials. JAMA 2001; 286: 1218-1227.
100. Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical activity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132: 605-611.
101. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011; 305: 1790-1799.
102. Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane DB Syst Rev 2009; CD003641.
103. International Diabetes Federation. Position statement: bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes. Brussels: International Diabetes Federation; 2011. http://www.idf.org/ webdata/docs/IDF-Position-Statement-Bariatric-Surgery.pdf.
104. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
105. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
106. Colagiuri S, Dickinson S, Girgis S, et al. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009. http:// www.nhmrc.gov.au/guidelines/publications/di19.
107. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
108. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
109. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
110. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
111. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
112. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
113. Ismail-Beigi F, Craven T, Banerji MA, et al, the ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430.
114. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
115. Duckworth W, Abraira C, Moritz T, et al, the VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
116. Riddle M, Rosenstock J, Gerich J. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
117. Nathan DM, Kuenen J, Borg R, et al, the A1C-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1-6.
118. International Diabetes Federation. Position statement: bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes. Brussels: International Diabetes Federation; 2011. http://www.idf.org/ webdata/docs/IDF-Position-Statement-Bariatric-Surgery.pdf.
119. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http:// www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf.
120. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
121. Colagiuri S, Dickinson S, Girgis S, et al. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009. http:// www.nhmrc.gov.au/guidelines/publications/di19.
122. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2002; 25: 750-786.
123. National Diabetes Information Clearinghouse. The A1C test and diabetes. NIH Publication No.: 11-7816. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2011.
124. Report of a World Health Organization Consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011; 93: 299-309.
125. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
126. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
127. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
128. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
129. Duckworth W, Abraira C, Moritz T, et al, the VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
130. Finke A, Kobold U, Hoelzel W, et al. Preparation of a candidate primary reference material for the international standardisation of HbA1c determinations. Clin Chem Lab Med 1998; 36: 299-308.
131. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia 2007; 50: 2042-2043.
132. Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A(1c) measurement. Diabetes Res Clin Pr 2010; 90: 228-230.
133. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-1478.
134. Sacks DB. Hemoglobin variants and hemoglobin A1c analysis: problem solved? Clin Chem 2003; 49: 1245-1247.
135. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112: 4284-4291.
136. Manley SE, Moore S, Smith JM, et al. When HbA1c for a patient does not reflect glycaemic control indicated by plasma glucose monitoring. Diabet Med 2008; 25: 256.
137. Kim C, Bullard KM, Herman WH, et al. Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2010; 33: 780-785.
138. Border DK, Round RA, Mason CL, et al. Raised fetal haemoglobin in patients with diabetes and other coexisting illnesses. Diabet Med 2011; 28: S164 P438.
139. Cappellini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassaemia 2nd edition revised 2008. Cyprus: Thalassaemia International Federation; 2008.
140. Vandewiele A, Genbrugge K, Delanghe J. Spuriously high HbA1c due to the presence of haemoglobin Raleigh: a case report and review of the literature. J Acta Clin Belg 2010; 65: 336-340 23.
141. Misra S, Hancock MR, Roper D, et al. Rare, 'fast' haemoglobin variants may interfere with HbA1c measurement using ion exchange high performance liquid chromatography: implications for diagnosis of diabetes. EASD 2012; Abstract No: A-1091. In press.
142. Mittman N, Desiraju B, Fazil I, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010; 117: S41-S45.
143. Manley SE, Gomes AN, McKnight JA, et al. When fructosamine results do not reflect glycaemic control indicated by other markers? Diabet Med 2009; 26: S154 P390.
144. Manley SE, Round RA, Nightingale PG, et al. How is fructosamine affected by urinary albumin excretion? Diabetes 2011; 60:SA2195-PO.
145. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476.
146. Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes Res Clin Pract 2008; 82: S118-S121.
147. American Diabetes Association. Bedside blood glucose monitoring in hospitals. Diabetes Care 2004; 27: S104.
148. Bot S, Davis TME, Davis WA, et al. Self-monitoring of blood glucose in type 2 diabetes: an inter-country comparison. Diabetes Res Clin Pract 2008; 82: e15-e18.
149. International Diabetes Federation. Self-monitoring of blood glucose in non-insulin treated type 2 diabetes. Brussels: International Diabetes Federation; 2009.
150. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http:// www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf.
151. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
152. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
153. Colagiuri S, Dickinson S, Girgis S, et al. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009. http:// www.nhmrc.gov.au/guidelines/publications/di19.
154. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
155. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
156. Towfigh A, Romanova M, Weinreb JE, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care 2008; 14: 468-475.
157. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29: 1757-1763.
158. Davis WA, Bruce DG, Davis ME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle diabetes study. Diabetologia 2007; 50: 510-515.
159. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with noninsulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 132.
160. Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; 336: 1177-1180.
161. O'Kane MJ, Bunting B, Copeland M, et al, the ESMON Study Group. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174-1177.
162. Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of selfmonitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallelgroup, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008; 10: 1239-1247.
163. International Diabetes Federation. 2011 Guideline for management of post meal glucose in diabetes. Brussels: International Diabetes Federation; 2011. http://www.idf.org.
164. French DP, Wade A, Yudkin P, et al. Self-monitoring of blood glucose changed non-insulin treated type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomised trial. Diabetic Med 2008; 25: 1218-1228.
165. Schwedes U, Siebolds M, Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002; 25: 1928-1932.
166. Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives. BMJ 2007; 335: 493.
167. Welschen LMC, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005; 28: 1510-1517.
168. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
169. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
170. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
171. Colagiuri S, Dickinson S, Girgis S, et al. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009. http:// www.nhmrc.gov.au/guidelines/publications/di19.
172. Qaseem A, Humphrey LL, Sweet DE, et al, the Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012; 156: 218-231.
173. International Diabetes Federation. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation; 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.
174. Bruno G, De Micheli A, Frontoni S, et al, Società Italiana di Diabetologia-Associazione Medici Diabetologi (SID-AMD) working group on the Standards of Care for Diabetes. Highlights from "Italian Standards of care for Diabetes Mellitus 2009- 2010". Nutr Metab Cardiovasc Dis 2011; 21: 302-314.
175. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2012; 55: 1577-1596.
176. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
177. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
178. Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-228.
179. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
180. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
181. van de Laar FA, Lucassen PL, Akkermans RP, et al. a-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
182. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
183. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. JAMA 2007; 298(2): 194-206.
184. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
185. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
186. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
187. Home PD, Pocock SJ, Beck-Nielsen H, et al, the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
188. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
189. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
190. Siebenhofer A, Plank J, Berghold A, et. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane DB Syst Rev 2009; CD003287.
191. Horvath K, Jeitler K, Berghold A, et al. Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane DB Syst Rev 2009; CD005613.
192. National Institute for Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. NICE Technology Appraisal Guidance No. 53. London: National Institute for Clinical Excellence; 2002. http://www.nice.org.uk.
193. Giugliano D, Maiorino MI, Bellastela G, et al. Treatment regimens with insulin analogues and haemoglobin A1c target of >7% in type 2 diabetes: a systematic review. Diab Res Clin Pr 2011; 92: 1-10.
194. Goudswaard AN, Furlong NJ, Valk GD, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane DB Syst Rev 2004; 4: CD003418.
195. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
196. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin therapy and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003; 26: 2598-2603.
197. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 1998; 317: 720-726.
198. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
199. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
200. National Vascular Disease Prevention Alliance. Evidencebased practice guidelines for the management of absolute cardiovascular disease risk. Canberra: NHMRC; 2012.
201. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
202. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian randomeffects meta-analyses of randomized trials. Circulation 2011; 123: 2799-2810.
203. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens 2011; 29: 1253-1269.
204. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
205. ADVANCE Collaborative Group, Patel A, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
206. Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45: 907-913.
207. Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and metaanalysis. Int Arch Med 2009; 2: 30.
208. Perez MI, Musini VM, Wright JM. Effect of early treatment with antihypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane DB Syst Rev 2009; 4: CD006743.
209. Yusuf S, Teo KK, Pogue J, et al, the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 2008; 358: 1547-1559.
210. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975.
211. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
212. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
213. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123: 1611-1621.
214. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
215. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-942.
216. Stevens R, Kothari V, Adler AI, et al. UKPDS 56: the UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes. Clin Sci 2001; 101: 671-679. www.dtu.ox.ac.uk/ index.php?maindoc=/riskengine.
217. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
218. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiov Prev R 2007; 14: Suppl 2.
219. National Vascular Disease Prevention Alliance. Evidencebased practice guidelines for the assessment of absolute cardiovascular disease risk. Canberra: NHMRC; 2009.
220. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: a summary resource for primary care practitioners. 2nd ed. Wellington: New Zealand Guidelines Group; 2009. http://www.moh.govt.nz and www. nzgg.org.nz.
221. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
222. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. Edinburgh: Scottish Intercollegiate Guidelines Network; 2007. (SIGN publication no. 97). http://www.sign.ac.uk/guidelines/fulltext/97/ index.html.
223. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007. http://whqlibdoc.who.int/publications/2007/9789241547178_ eng.pdf.
224. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
225. Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
226. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
227. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170: 1024-1031.
228. Colhoun HM, Betteridge DJ, Durrington PN, et al, the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
229. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane DB Syst Rev 2011; 1: CD004816.
230. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 14: 1-160, iii-iv.
231. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-463.
232. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875-1884.
233. Allemann S, Diem P, Egger M, et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin 2006; 3: 617-623.
234. Keech A, Mitchell P, Summanen P, et al, the FIELD study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
235. Rajamania P, Colman P, Lia L, et al, the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.
236. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
237. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
238. Antiplatelet Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
239. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
240. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313.
241. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300-2306.
242. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.
243. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a metaanalysis. Diabetes Res Clin Pract 2010; 87: 211-218.
244. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
245. British Heart Foundation. ASCEND: A Study of Cardiovascular Events iN Diabetes. http://www.ctsu.ox.ac.uk/ascend.
246. Chibber R, Chibber S, Kohner EM. 21st century treatment of diabetic retinopathy. Expert Rev Endocrinol Metab 2007; 2: 623-631.
247. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 182: 527-532.
248. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of DRS findings. DRS Report No. 8. Ophthalmology 1981; 88: 583-600.
249. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS Report No. 9. Ophthalmology 1991; 98: 741-756.
250. Wilkinson CP, Ferris FL 3rd, Klein RE, et al, the Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.
251. Whited JD. Accuracy and reliability of teleophthalmology for diagnosing diabetic retinopathy and macular edema: a review of the literature. Diabetes Technol Ther 2006; 8: 102-122.
252. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998; 116: 297-303.
253. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-1474.
254. Younis N, Broadbent DM, Vora JP, et al. Incidence of sight threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361: 195-200.
255. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http:// www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf.
256. American Diabetes Association. Clinical practice recommendations 2012. Diabetes Care 2012; 35: Suppl 1.
257. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http://www.diabetes.ca.
258. Australian Diabetes Society for the Department of Health and Ageing. Guidelines for the management of diabetic retinopathy. Canberra: National Health and Medical Research Council; 2008. www.nhmrc.gov.au/publications.
259. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes: a national clinical guideline, 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
260. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
261. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-713.
262. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
263. Zoungas S, de Galen B, Ninomiya T, et al, the Advance Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. New results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
264. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
265. Kidney Foundation Disease Outcomes Quality Initiative. K/ DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
266. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
267. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes: a national clinical guideline, 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
268. Chadban S, Howell M, Twigg S, et al. National evidence based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009.
269. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http:// www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf.
270. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
271. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
272. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-713.
273. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
274. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
275. National evidence-based guideline on prevention, identification and management of foot complications in diabetes (part of the guidelines on management of type 2 diabetes). Melbourne: Diabetes Australia and the NHMRC; 2011. http:// www.diabetesaustralia.com.au.
276. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes: a national clinical guideline, 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
277. Bakker K, Apelqvist J, Schaper NC, et al, the International Working Group on the Diabetic Foot Editorial Board. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev 2012; 28: 225-231.
278. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
279. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
280. National Institute for Clinical Excellence. Type 2 diabetes - footcare. London: National Institute for Clinical Excellence; 2004. http://www.nice.org.uk/page.aspx?o=101518.
281. Dorresteijn JA, Kriegsman DM, Assendelft WJ, et al. Patient education for preventing diabetic foot ulceration. Cochrane DB Syst Rev 2010; 5: CD001488.
282. Schaper NC, Andros G, Apelqvist J, et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2012; 28: 218-224.
283. Scottish Intercollegiate Guidelines Network. SIGN 116. Management of diabetes: a national clinical guideline, 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
284. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
285. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
286. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
287. Boulton AJ, Vinik AI, Arezzo JC, et al, the American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
288. Freeman R, Durso-Decruz E, Emir B. Efficacy safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454.
289. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence- based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel- group studies. Clin Ther 2007; 29: S2536-S2546.
290. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
291. Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies (technical review). Diabetes Care 2004; 27: 1458-1486.
292. Vinik AI, Maser RE, Mitchell B, et al. Diabetic autonomic neuropathy: a technical review. Diabetes Care 2003; 26: 1553-1579.
293. Moore M. Nutrition therapy for diabetic gastropathy. In: Franz MJ, Evert AB (eds). American Diabetes Association guide to nutrition therapy for diabetes. 2nd ed. Alexandria, VA: American Diabetes Association; 2012: 355-369.
294. Scott A. Screening for malnutrition in the community: the MUST tool. Br J Community Nurs 2008; 13: 410-412.
295. Australian Diabetes Educators Association. Guidelines for the management and care of diabetes in the elderly. Weston, ACT: Australian Diabetes Educators Association; 2003.
296. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. California Healthcare Foundation/American Geriatrics Society Panel on improving care for elders with diabetes. J Am Geriatr Soc 2003; 51: S265-S280.
297. Sinclair AJ, Paolisso G, Castro M, et al, the European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011; 37: S27-S38.
298. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
299. Task and Finish Group of Diabetes UK. Good clinical practice guidelines for care home residents with diabetes. London: Diabetes UK; 2011. http://www.diabetes.org.uk.
300. Resnick HE, Harris MI, Brock DB, et al. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000; 23: 176-180.
301. Garcia R, Suarez R. Diabetes education in the elderly: a 5 year follow-up of an interactive approach. Patient Educ Couns 1997; 29: 87-97.
302. Bruce DG, Davis WA, Davis TME. Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes. Diabetes Care 2005; 28: 2441-2447.
303. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the women's health initiative observational study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
304. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116: 1094-1105.
305. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes-a systematic review. Lancet Neurol 2006; 5: 64-74.
306. Ryan CM, Freed MI, Rood JA, et al. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006; 29: 345-351.
307. Gonzalez J, Safren S, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007; 30: 2222-2227.
308. Sinclair AJ. Towards a minimum data set for intervention studies in type 2 diabetes in older people. J Nutr Health Aging 2007; 11: 289-293.
309. Sinclair AJ, Gadsby R, Penfold S, et al. Prevalence of diabetes in care home residents. Diabetes Care 2001; 24: 1066-1068.
310. Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008: 149: 11-19.
311. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30: 3017-3022.
312. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomised elderly patients with type 2 diabetes mellitus. JAGS 2007; 55: 182-188.
313. Beckett NS, Peters R, Fletcher AE, et al, the YVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1887-1898.
314. Baigent C, Keech A, Kearney PM, et al, the Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
315. Colhoun HM, Betteridge DJ, Durrington PN, et al, the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
316. Keech A, Simes RJ, Barter P, et al, the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
317. American Association of Diabetes Educators. Special considerations in the management and education of older persons with diabetes. Diabetes Educ 2009; 35: S11-S63.
318. Suhl E, Bunsignore P. Diabetes self-management education for older adults: general principles and practical application. Diabetes Spect 2006; 19: 234-250.
319. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
320. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32: 1119-1131.
321. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
322. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-597.
323. Finfer S, Chittock DR, Su SY, et al, the NICE-SUGAR Study investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
324. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a metaanalysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-827.